Post-COVID Condition Risk Factors and Symptom Clusters and Associations with Return to Pre-COVID Health-Results from a 2021 Multi-State Survey.

Publication date: Dec 20, 2024

Little is known about how symptoms or symptom clusters of Post-COVID Conditions (PCC) impact an individual’s return to pre-COVID health. We used four state-level COVID-19 case reporting systems and patient-reported survey data to identify patients with PCC and associations with an individual’s return to pre-COVID health after laboratory-confirmed SARS-CoV-2 infection. Participants had a positive SARS-CoV-2 test between March-December 2020. Weighted regression models were used to 1) estimate prevalence of PCC; 2) identify risk factors associated with developing PCC; and 3) examine associations between PCC symptom clusters and return to pre-COVID health. Factor analysis was used to statistically identify post-COVID symptom clusters. Prevalence of PCC in this population-based sample was 29.9% for persons with SARS-CoV-2 infection, during the pre-delta variant period (March-December 2020); 77.2% of persons experiencing PCC had not returned to pre-COVID health within 8-60 weeks after infection. Female sex, acute COVID-19 illness severity, and number of pre-existing comorbidities were significant risk factors associated with PCC. Myalgic encephalomyelitis/chronic fatigue syndrome-like symptoms, upper-respiratory symptoms, and gastrointestinal symptoms were significantly associated with not returning to pre-COVID health. Understanding PCC symptom clustering may provide insight into pathophysiology, severity of PCC, and management for patients who have not returned to their usual state of health after SARS-CoV-2 infection. Tracking PCC can help measure the impact of COVID-19 vaccination and acute COVID-19-specific treatments on reducing PCC in the US.

Concepts Keywords
Pathophysiology Long COVID
Pcc Post-COVID condition
Vaccination prevalence
risk factors
SARS-CoV-2
symptom clusters

Semantics

Type Source Name
disease MESH Post-COVID Condition
disease MESH Symptom Clusters
drug DRUGBANK Factor IX Complex (Human)
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH Myalgic encephalomyelitis
disease IDO symptom
disease MESH sequelae

Original Article

(Visited 1 times, 1 visits today)